Aldevron and Inscripta ink manufacturing deal for CRISPR Type-V nuclease
A plan to broaden access to CRISPR has attracted a chunk of funding and is now seeing its wings spread.
Fargo-based DNA and mRNA producer Aldevron has signed an agreement with life sciences company Inscripta to manufacture and commercialize the Eureca-V Nuclease, a wild-type MAD7 CRISPR Type-V nuclease.
This partnership will aim to offer this nuclease as a standard research-grade and GMP catalog item. According to a press release, the production of Eureca-V is slated to start in Q3 of 2022. Financial details of the deal were not immediately made available to Endpoints News.
This license also expands access to high-quality CRISPR reagents, enabling clients to receive access to and translate their research into cell therapies, especially allogenic cell treatments. The MAD7 is billed by Inscripta as a synthetic enzyme and may serve as an alternative to Cas9 that is free for scientific research, without the licensing fee tied to the original CRISPR molecule.
“Eureca-V will be our third GMP CRISPR nuclease and the first Type-V nuclease available as a GMP catalog product, enabling access to a clinical-grade reagent in a fraction of the time and the cost of manufacturing a custom batch. By offering an identical product at research grade, clients can expect a smooth transition from proof of concept all the way to the clinic,” said Tom Foti, VP of Aldevron’s protein business unit.
Aldevron is already in a strong position as one of the top manufacturers of plasmid DNA, mRNA and proteins. The company also is a supplier for a host of gene and cell therapy, and gene editing players.
Inscripta has been scaling heavily in the gene editing field. The Boulder biotech received a total of $260 million in their various fundraisings and another $150 million from investors in 2021 for their engineering platform around the MAD7.
For Aldevron, this is another feather in its cap as it continues to grow. In 2021, Danaher struck a deal to purchase the company for the price of a $9.6 billion cash deal but act as an independent unit. Aldevron’s majority owner used to be EQT Private Equity, which invested in the company alongside its founders.
Aldevron expanded its capabilities in Fargo to include 189,000 square feet of manufacturing, warehouse, and logistical space. Early in 2021, the company also completed a renovation and expansion project in Madison, Wisconsin.